Condition: Healthy · Sponsor: Tel-Aviv Sourasky Medical Center
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions. Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.
This description comes directly from the study's public registry record.
Irit Avivi, Prof · -97236973782 · iritavi@tlvmc.gov.il
Ella Krayzler · -97236947231 · ellakr@tlvmc.gov.il
Always discuss trial participation with your own doctor first.
| Soroka | Beersheba, Israel | Recruiting |
| Rabin medical center | Petah Tikva, Israel | Recruiting |
| TASMC | Tel Aviv, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05837884